Sofinnova Investments, Inc. Inhibrx, Inc. Transaction History

Sofinnova Investments, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Aug 14, 2024	BUY	$32.76 - $39.56 $42.7 Million - $51.5 Million	1,302,645 New	1,302,645 $45.5 Million
Q1 2024 May 15, 2024	BUY	$32.76 - $39.56 $17.4 Million - $21 Million	529,688 Added 68.53%	1,302,645 $45.5 Million
Q4 2023 Aug 15, 2024	BUY	$14.5 - $38.0 $11.2 Million - $29.4 Million	772,957 New	772,957 $29.4 Million
Q4 2023 Feb 12, 2024	SELL	$14.5 - $38.0 $3.27 Million - $8.56 Million	-225,326 Reduced 22.57%	772,957 $29.4 Million
Q2 2023 Aug 14, 2023	SELL	$16.96 - $27.82 $4.18 Million - $6.85 Million	-246,205 Reduced 19.78%	998,283 $25.9 Million
Q1 2023 May 11, 2023	BUY	$18.45 - $27.14 $2.48 Million - $3.65 Million	134,305 Added 12.1%	1,244,488 $23.5 Million
Q4 2022 Feb 13, 2023	BUY	$20.18 - $33.33 $13.3 Million - $22 Million	660,006 Added 146.61%	1,110,183 $27.4 Million
Q3 2022 Nov 08, 2022	BUY	$11.58 - $24.73 $3.5 Million - $7.47 Million	302,242 Added 204.31%	450,177 $8.08 Million
Q2 2022 Aug 15, 2022	SELL	$8.52 - $25.26 $3.12 Million - $9.26 Million	-366,705 Reduced 71.25%	147,935 $1.68 Million
Q1 2022 May 16, 2022	BUY	$19.89 - $43.18 $2.9 Million - $6.3 Million	145,961 Added 39.59%	514,640 $11.5 Million
Q4 2021 Feb 14, 2022	BUY	$26.75 - $46.02 $9.86 Million - $17 Million	368,679 New	368,679 $16.1 Million

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $626M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Sofinnova Investments, Inc., based on Form 13F filings with the SEC.

Stay updated on Sofinnova Investments, Inc. with notifications on news.